AstraZeneca PLC
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. Graeme Sloan | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The race to develop more convenient […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Beijing pledges greater market access as top global CEOs gather at the China Development Forum
Chinese Vice Premier He Lifeng (R) shakes hands with US Senator Steve Daines before a meeting held in the Xinjiang Room at the Great Hall of the People in Beijing on March 22, 2025. Ng Han Guan | Afp | Getty Images China’s Vice Premier He Lifeng has reassured foreign business leaders that Beijing will […]
Read More
CNBC Daily Open: Tariff flexibility sounds good, but also signals uncertainty
A cargo ship full of shipping containers is seen at the port of Oakland, as trade tensions escalate over U.S. tariffs, in Oakland, California, U.S., March 6, 2025. Carlos Barria | Reuters “Flexibility” connotes openness to change. U.S. President Donald Trump expressed Friday the possibility of being flexible with tariffs, which may have helped stocks […]
Read More
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
Outside the Macclesfield factory of AstraZeneca. Christopher Furlong | Getty Images News | Getty Images British pharmaceutical giant AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing. The new hub is expected to take AstraZeneca’s Beijing workforce to around 1,700 employees. Don’t miss AstraZeneca’s CEO […]
Read More
Healthy Returns: AbbVie is the newest potential weight loss drug market player
A sign stands outside an Abbvie facility in Cambridge, Massachusetts. Brian Snyder | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The booming weight loss drug market has gained a new potential competitor. AbbVie […]
Read More
Maersk jumps 7.5% on earnings beat, Volvo Cars retreats 6% amid warnings of market challenges
Danish brewer Carlsberg slightly misses on fourth-quarter sales, points to slower growth in 2025 Danish brewer Carlsberg on Thursday reported a slight miss in fourth-year sales and pointed to lower growth in 2025. The company posted fourth-quarter sales to 15.72 Danish kroner ($2.18 billion), coming in just below the 15.79 billion Danish kroner estimated by analysts in […]
Read More
Stock futures are little changed after S&P 500 posts back-to-back winning sessions: Live updates
Traders work on the floor of the New York Stock Exchange on Feb. 4, 2025. NYSE U.S. stock futures were little changed Wednesday night after the major averages posted back-to-back winning sessions. Futures tied to the Dow Jones Industrial Average were marginally higher. S&P 500 futures and Nasdaq 100 futures were both trading around flat. […]
Read More
CNBC’s Inside India newsletter: A slowing economy hasn’t dimmed India’s allure at Davos
The World Economic Forum in Davos on January 20, 2025. Fabrice Coffrini | AFP | Getty Images This report is from this week’s CNBC’s “Inside India” newsletter which brings you timely, insightful news and market commentary on the emerging powerhouse and the big businesses behind its meteoric rise. Like what you see? You can subscribe here. […]
Read More
J&J says its lung cancer drug combination keeps people alive longer
Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically […]
Read More